Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial

Abstract

General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

“…Costs for running Oncokompas (ICT, product and data management, content updating, implementation, and marketing) are estimated at €450,000 annually. When reaching 18,000 cancer survivors per year (16% of all newly diagnosed cancer patients in the Netherlands) [14,23], the intervention costs are estimated at €25 per user.…”

“…Survivors who were still receiving endocrine therapy or immunotherapy, or had a wait-and-see regimen, were included 3 months after their previous treatment or diagnosis, respectively. Exclusion criteria were the following: no access to the Internet or no email address, severe cognitive impairment, insufficient mastery of the Dutch language, physical inability to complete a questionnaire, and male breast cancer survivors [14,16].…”

“…Oncokompas was developed according to a participatory design approach, including all relevant stakeholders in each step of the development [9,12]. A detailed description of Oncokompas can be found elsewhere [10,12,14,16].…”

“…Oncokompas can be used by cancer survivors independently from a healthcare provider and follows a tailored care approach: all cancer survivors receive tailored information, advice, and tips; survivors with minor symptoms are referred to self-help interventions while survivors with major symptoms are primarily referred to professional care. Recently, we showed that Oncokompas has small, but significant effects on improving HRQOL and reducing the burden of several tumour-specific symptoms among cancer survivors [14].…”

Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients

“…In judging the curative efficacy, prolonged survival does not always mean improved health outcomes ( 16 ). Nowadays, the importance of health outcomes, equivalent to the remission rate and survival time, is increasingly attracting attention and has been regarded as an outcome indicator in cancer research ( 17 , 18 ). In order to understand the impact of the FOLFIRI and mFOLFOX6 regimens on the health outcomes of cancer patients, in this study, these two chemotherapy regimens were evaluated and compared, for the first time to our best knowledge, among different solid tumor patients after adjusting the impact of relevant factors such as disease.…”